FOXO4-DRI Dosing Protocol
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt FOXO4-p53 interactions in senescent cells, triggering selective apoptosis. It represents one of the most targeted senolytic interventions studied, though human data is extremely limited.
Key Points
Step-by-Step Guide
Understand the Mechanism
FOXO4-DRI competes with natural FOXO4 for p53 binding in senescent cells, causing p53 to relocalize to mitochondria and trigger apoptosis selectively in senescent cells while sparing healthy cells.
Research Dosing
Mouse studies used 5 mg/kg intraperitoneal or intravenous. Human-equivalent dose estimations vary widely. The research community discusses 10-50 mg subcutaneously per treatment session.
Cycle Design
Senolytic protocols are inherently intermittent: 3 consecutive days of treatment, then 2-4 weeks off. Senescent cells do not repopulate rapidly, allowing long intervals between treatments.
Frequency
3-5 treatment cycles per year is the most discussed approach. The "hit and run" strategy targets accumulated senescent cells without continuous exposure.
Monitor Biomarkers
Senescence-associated biomarkers (p16INK4a, SASP markers, SA-beta-gal) can be measured but require specialized testing. Subjective markers include energy, skin quality, and inflammatory symptoms.
Warnings & Precautions
- !Extremely limited human safety data—this is highly experimental.
- !FOXO4-DRI is one of the most expensive research peptides.
- !Potential for unintended apoptosis in non-target cells is not fully characterized.
- !D-retro-inverso peptides have unique pharmacokinetics not well understood.
Frequently Asked Questions
What are senescent cells?
Cells that have permanently stopped dividing but resist apoptosis, accumulating with age. They secrete inflammatory factors (SASP) contributing to aging and age-related diseases. Senolytics like FOXO4-DRI aim to selectively eliminate them.
Why is FOXO4-DRI so expensive?
As a D-retro-inverso peptide, every amino acid is a D-isomer and the sequence is reversed. This makes synthesis significantly more complex and costly than standard L-peptides. Doses are also relatively large (mg range).
How does FOXO4-DRI compare to other senolytics?
Pharmaceutical senolytics (dasatinib + quercetin) are far better studied, cheaper, and more accessible. FOXO4-DRI offers a potentially more targeted mechanism but with far less clinical evidence. Most researchers start with D+Q before considering FOXO4-DRI.